Logo

New Products: NuGen's Ovation Target Enrichment; HTG Molecular's EdgeSeq Assay

Jun 10, 2014
Premium

NuGen has launched its Ovation Target Enrichment System, which uses NuGen's proprietary single primer enrichment technology. The firm has also launched two oncology panels — Ovation Cancer Panel Target Enrichment, which targets over 300 cancer genes, and Ovation Gene Fusion Target Enrichment, which targets over 400 cancer genes that are involved in gene fusions.

HTG Molecular Diagnostics has launched HTG EdgeSeq miRNA Whole Transriptome Assay to analyze the expression of 2,275 microRNAs that are described in the miRBase v20 database. The assay works with formalin-fixed paraffin-embedded tissue samples, is automated on the HTG Edge System and couples HTG Molecular's proprietary nuclease protection chemistry with next-generation sequencing.

Filed under

Clinical Sequencing
Sequencing
Next-Generation Sequencing
Breaking News
The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.